Noelle Cloven, MD
Gynecologic Oncology · Fort Worth, TXNPI 1477518686
Payments from drug & device makers
Across 1,118 payments — averaging $6532.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3.7M
- Tesaro, Inc.$1.2M
- Merck$724K
- Genmab U.S., Inc.$700K
- Pfizer$525K
- Alkermes, Inc.$134K
- plus $345K from 21 others
What the payments were for
- Consulting fees$14,75882%
- Travel & lodging$2551%
- Food & beverage$2,91516%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 226 | $3,655,972 |
| Tesaro, Inc. | 58 | $1,219,529 |
| Merck | 23 | $723,857 |
| Genmab U.S., Inc. | 21 | $700,131 |
| Pfizer | 54 | $525,260 |
| Alkermes, Inc. | 9 | $133,712 |
| Genentech, Inc. | 17 | $123,264 |
| Karyopharm Therapeutics Inc. | 49 | $103,416 |
| AstraZeneca | 8 | $43,853 |
| Daiichi Sankyo Inc. | 185 | $42,645 |
| Incyte Corporation | 411 | $16,733 |
| Seagen Inc. | 29 | $11,831 |
| AbbVie | 9 | $2,554 |
| Corcept Therapeutics | 3 | $306 |
| Stryker | 2 | $141 |
| Immunogen, Inc. | 1 | $119 |
| Biontech SE | 1 | $118 |
| Gilead | 3 | $92 |
| Novocure Inc. | 1 | $58 |
| Novartis | 1 | $25 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $18 |
| Sanofi | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$5,585
- EPKINLY$1,965
- ZEJULA$1,300
- Elahere$480
- SPY-PHI SYSTEM$126
How this compares
$7,303,734 in reported general payments places this provider in the 95th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 12 | $278,091 |
| Megestrol Acetate | 21 | $1,672 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 82 | $1,098 |
| Dexamethasone | 26 | $452 |
| Letrozole | 22 | $378 |
| Gabapentin | 29 | $187 |
| Imiquimod | 11 | $118 |
| Ondansetron Hcl | 19 | $97 |
| Tramadol Hcl | 20 | $96 |
| Olanzapine | 17 | $49 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Fort Worth
- Reagan StreetFort Worth$280K
- Tiffany RedfernFort Worth$165K
- Christopher LafargueFort Worth$26K
- de Ette VasquesFort Worth$19K
- Pamela SolimanHouston$30.7M
- Christine LeeShenandoah$6.3M
- Antonio Santillan-GomezSan Antonio$4.5M
- Jayanthi LeaDallas$3.9M
- Helen EshedAustin$3.5M
- Robert ColemanHouston$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.